Kina Höglund

TL;DR: Blood p-tau181 can predict tau and amyloid β pathologies, differentiate Alzheimer's disease from other neurodegenerative disorders, and identify Alzheimer's Disease across the clinical continuum.

TL;DR: The findings further support the conclusion that there is no change in APP expression in sporadic AD, as the level of CSF-beta-sAPP was significantly increased in patients with mild cognitive impairment compared to controls, and the relationship between the CSF level of alpha/beta-SAPP and Abeta and the apoE epsilon 4 (apoE4) allele was investigated.

TL;DR: Cerebrospinal fluid levels of neurofilament light (NFL) protein, a marker of neuroaxonal degeneration, in control participants and patients with dementia, motor neuron disease, and parkinsonian disorders are investigated to determine its association with longitudinal cognitive decline.

TL;DR: The objective was to compare the levels of three synaptic proteins involved in different steps of the synaptic transmission: Rab3A, SNAP25, and neurogranin, in three common forms of dementia: Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease dementia.

TL;DR: The unchanged level of plasma-Aβ(1–42) in contrast to the marked increase in VCSF-A β(1-42) after severe TBI, supports the suggestion that plasma Aβ( 1–42), which is mainly composed of aggregated β-amyloid, does not reflect Aβ metabolism in the central nervous system (CNS).